Vyvanse Dosing for Binge Eating Disorder
Start Vyvanse at 30 mg once daily in the morning, then titrate by 20 mg increments at weekly intervals to reach the target dose of 50-70 mg daily, with a maximum of 70 mg/day. 1
Dosing Algorithm
Initial Dosing
- Starting dose: 30 mg once daily in the morning
- Administration: Take with or without food; avoid afternoon doses due to insomnia risk 1
Titration Schedule
- Increment: Increase by 20 mg at approximately weekly intervals 1
- Target dose: 50-70 mg once daily 1
- Maximum dose: 70 mg once daily 1
Treatment Duration Decision Point
- Discontinue if no improvement: Stop Vyvanse if binge eating does not improve 1
- The FDA label provides this clear directive without specifying an exact timeframe, though pivotal trials showed efficacy as early as Week 1 2
Special Populations Requiring Dose Adjustment
Renal Impairment
- Severe renal impairment (GFR 15 to <30 mL/min/1.73 m²): Maximum 50 mg daily 1
- End-stage renal disease (GFR <15 mL/min/1.73 m²): Maximum 30 mg daily 1
Drug Interactions Affecting Dosing
Agents altering urinary pH require dose adjustment 1:
- Acidifying agents (e.g., ascorbic acid): Decrease amphetamine blood levels—may need higher Vyvanse doses
- Alkalinizing agents (e.g., sodium bicarbonate): Increase amphetamine blood levels—may need lower Vyvanse doses
Clinical Context from Guidelines
The 2023 APA guidelines position lisdexamfetamine as a second-line option for binge eating disorder 3. Psychotherapy (CBT or interpersonal therapy) should be the first-line treatment 3. The APA suggests (2C recommendation—indicating moderate uncertainty) that lisdexamfetamine be used for adults who either prefer medication or have not responded to psychotherapy alone 3.
This hierarchical approach reflects that while lisdexamfetamine has proven efficacy, psychotherapy remains the foundation of BED treatment. The medication is FDA-approved specifically for moderate to severe BED in adults 1.
Evidence Supporting This Dosing
The 50-70 mg target dose range is supported by two pivotal Phase 3 trials showing significant reductions in binge eating days per week compared to placebo 4. The weekly 20 mg titration schedule balances achieving therapeutic effect quickly (improvements seen as early as Week 1 2) while allowing tolerability assessment.
Recent 2025 data confirms that combined CBT+LDX produces superior outcomes to either treatment alone, with 70.2% remission rates versus 44.7% for CBT alone and 40.4% for LDX alone 5. This reinforces that medication works best as part of comprehensive treatment rather than monotherapy.
Common Pitfalls to Avoid
- Don't use for weight loss: Vyvanse is not indicated for obesity treatment; use only for BED 1
- Don't split doses: Take as single daily morning dose; do not divide capsules/tablets 1
- Don't continue indefinitely without response: Reassess if binge eating hasn't improved and consider discontinuation 1
- Don't forget cardiac screening: Assess for cardiac disease before initiating treatment 1
Tolerability Profile
Most common adverse events (≥10% incidence) include dry mouth (27.2%), headache (13.2%), insomnia (12.4%), and upper respiratory tract infection (11.4%) in long-term studies 6. These are generally mild to moderate in severity. Mean increases in pulse (6.58 bpm) and blood pressure (systolic 2.19 mmHg, diastolic 1.77 mmHg) occur but are typically manageable 6.